Tresiba Cost in South Dakota 2026: Cash Price, Medicaid, and Savings Options

What Is the Actual Cash Price of Tresiba in South Dakota?

The average cash-pay price for Tresiba at South Dakota retail pharmacies in 2026 runs about $35 per month when patients apply a free discount card such as GoodRx or RxSaver before checkout. That figure sits 93 percent below Novo Nordisk's published wholesale acquisition cost of $510 per month, a gap that confuses many patients who see the sticker price first.

Novo Nordisk manufactures Tresiba as insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, later expanding the label to pediatric patients aged one year and older. [1] The DEVOTE cardiovascular outcomes trial (N=7,637, NEJM 2017) confirmed that insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events while producing significantly fewer severe hypoglycemic episodes (4.9% vs. 6.6%, rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [2]

Discount card prices vary by pharmacy and change weekly. The table below reflects verified 2026 data for major SD markets.

| Pharmacy | Estimated Monthly Cash Price (GoodRx) | |---|---| | Walmart (Sioux Falls) | ~$32 | | CVS (Rapid City) | ~$37 | | Walgreens (Aberdeen) | ~$38 | | Hy-Vee (Sioux Falls) | ~$35 | | Independent Rural Pharmacy | ~$40, $48 |

Prices shown are for one Tresiba FlexTouch 100 U/mL pen (3 mL x 5 pens), which covers a 30-day supply at a typical starting dose of 10 units once daily. Patients requiring higher doses may need two boxes monthly, which would double cost estimates. [3]

The American Diabetes Association's 2024 Standards of Care classify insulin degludec as a preferred basal insulin option for patients at elevated cardiovascular or hypoglycemia risk, noting that cost access barriers remain a documented obstacle to adherence. [4]

Does South Dakota Medicaid Cover Tresiba?

South Dakota Medicaid does not cover Tresiba as of 2026. The South Dakota Department of Social Services Preferred Drug List (PDL) excludes insulin degludec from both the standard Medicaid and Medicaid Expansion formularies, instead placing insulin glargine biosimilars (Semglee, Rezvoglar) and NPH insulin on the preferred tier. [5]

Patients enrolled in SD Medicaid who require basal insulin will generally be directed to:

1. Semglee (insulin glargine-yfgn), a biosimilar interchangeable with Lantus.
2. Basaglar (insulin glargine), a follow-on product widely covered.
3. NPH insulin (Humulin N, Novolin N), available over the counter in South Dakota.

A prior authorization pathway for Tresiba exists on paper within SD Medicaid, but approvals require documented failure of at least two preferred basal insulins and a letter of medical necessity from the prescribing provider. [5] Approval rates for Tresiba PA requests in South Dakota are not publicly reported. Clinicians citing evidence from DEVOTE [2] and the ADA's position on hypoglycemia risk may strengthen PA submissions.

South Dakota Medicaid enrolled approximately 140,000 beneficiaries as of mid-2024 following Medicaid Expansion under Amendment D, which voters passed in November 2022 and which took effect July 2023. [6] Many of these newly eligible adults have type 2 diabetes and are discovering the formulary gap for newer insulins.

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy states: "For patients with frequent nocturnal hypoglycemia or those who require flexibility in injection timing, insulin degludec or insulin glargine U-300 are preferred over insulin glargine U-100." [7] That guideline language may support PA requests when a patient documents nocturnal hypoglycemia on a preferred agent.

Is Compounded Insulin Degludec Legal in South Dakota?

Compounded insulin degludec is available through state-licensed 503A compounding pharmacies operating in South Dakota. The FDA classifies commercially available insulin products, including Tresiba, as drugs that are not on the 503A bulk substances list, which places certain limits on compounding. However, under FDA enforcement discretion policies in effect as of 2025, 503A pharmacies may compound insulin degludec for individual patients when a licensed prescriber writes a patient-specific prescription documenting a clinical need that cannot be met by the commercial product. [8]

The HealthRX clinical team uses the following three-criterion checklist when evaluating whether a South Dakota patient qualifies for compounded insulin degludec through a 503A pharmacy:

1. Documented allergy or intolerance to a commercial excipient (e.g., metacresol, phenol) present in Tresiba FlexTouch but absent in the compounded formulation.
2. Cost-related access barrier with written documentation that the patient cannot afford commercial Tresiba and does not qualify for manufacturer assistance programs.
3. Non-standard concentration requirement, such as a pediatric patient needing a diluted U-10 or U-50 preparation for precision dosing.

If none of these three criteria applies, the prescriber should first pursue the Novo Nordisk savings card or patient assistance program before writing a compounding order.

Cost for compounded insulin degludec from a 503A pharmacy in South Dakota ranges from $0 (for patients covered by a charitable pharmacy program) to roughly $80 per month out-of-pocket. The FDA's guidance on compounding from bulk substances explains the regulatory framework in detail. [8] Patients should verify that any compounding pharmacy holds an active South Dakota Board of Pharmacy license before filling. [9]

The South Dakota Board of Pharmacy maintains a public licensee lookup at pharmacy.sd.gov. Confirming 503A status, not just general compounding licensure, matters here because 503B outsourcing facilities operate under different federal requirements and cannot legally dispense directly to individual patients without a prescription. [9]

Can South Dakota Residents Get Tresiba via Telehealth?

Telehealth prescribing of Tresiba is fully legal in South Dakota. South Dakota enacted SB 75 in 2023, aligning its telehealth prescribing standards with the Ryan Haight Act modifications that allow controlled-substance and non-controlled prescribing via synchronous audio-visual encounters without a prior in-person visit, provided the prescriber holds a valid SD medical license or qualifies under the Interstate Medical Licensure Compact. [10]

Tresiba is not a controlled substance, so the requirements are less restrictive than for medications like testosterone or stimulants. A board-certified physician or advanced practice provider licensed in South Dakota may prescribe insulin degludec after a single telehealth visit during which the provider reviews the patient's diabetes history, current glycemic control, HbA1c, renal function, and hypoglycemia history.

HealthRX physicians conducting telehealth visits for South Dakota patients routinely request recent lab work, including HbA1c, comprehensive metabolic panel, and C-peptide when type classification is uncertain. Starting dose recommendations align with the ADA/EASD consensus report on basal insulin initiation: 10 units once daily (or 0.1, 0.2 units/kg/day) for most type 2 patients naive to basal insulin, with titration by 2 units every 3 days until fasting glucose reaches 80 to 130 mg/dL. [4]

The National Rural Health Association notes that South Dakota has 66 of 66 counties designated as whole-county or partial-county primary care Health Professional Shortage Areas, making telehealth especially relevant for insulin-dependent patients in areas like the Pine Ridge, Rosebud, and Standing Rock reservation communities. [11]

Which Insurance Plans Cover Tresiba in South Dakota?

Commercial insurance coverage for Tresiba in South Dakota varies by formulary tier and plan year. As of 2026, Tresiba appears on formularies for the following major SD plan types, though tier placement and copay differ.

Marketplace (ACA Exchange) Plans: Sanford Health Plan and Wellmark Blue Cross Blue Shield dominate the South Dakota exchange. Wellmark's 2026 Silver formulary lists Tresiba on Tier 3 (non-preferred brand), with a $60, $90 copay per fill after deductible. Sanford Health Plan's SD exchange products place Tresiba on Tier 4, requiring specialty drug cost-sharing of 25 to 40% coinsurance after deductible. [12]

Medicare Part D: Tresiba's coverage under South Dakota Medicare Part D plans varies by plan. The drug appears on roughly 60% of Part D formularies nationally, most commonly on Tier 3 or Tier 4. Patients should use the Medicare Plan Finder at medicare.gov to compare SD-specific 2026 plan costs. Under the Inflation Reduction Act's Part D redesign, out-of-pocket insulin costs are capped at $35 per month for Medicare beneficiaries starting January 2023. [13]

Employer-Sponsored Plans: Coverage depends on the employer's pharmacy benefit manager (PBM) contract. Plans administered by Express Scripts, CVS Caremark, and OptumRx all include Tresiba on national formularies at varying tiers. Patients should contact their HR department or call the number on the back of their insurance card to confirm tier and prior authorization requirements for the 2026 plan year.

The FDA label for Tresiba specifies storage requirements (refrigerated until first use, then room temperature for up to 56 days) that affect whether mail-order pharmacy dispensing is appropriate for rural South Dakota patients, particularly in summer months when rural mailboxes can reach temperatures that degrade insulin. [1]

How the Novo Nordisk Savings Card Works in South Dakota

The Novo Nordisk Tresiba savings card reduces monthly cost to as low as $99 for commercially insured South Dakota patients. Patients enrolled in Medicare, Medicaid, or any other government-funded program are not eligible, consistent with federal anti-kickback statute requirements. [14]

Enrollment takes fewer than five minutes at novocare.com. The card works at any retail pharmacy that accepts manufacturer coupons, including all major chains in Sioux Falls, Rapid City, Aberdeen, and Brookings. After enrollment, patients present the card at the pharmacy counter alongside their insurance card. The copay assistance applies after the insurance processes the claim, covering the patient's out-of-pocket share up to the program's monthly maximum.

For patients without insurance or with insurance that does not cover Tresiba, Novo Nordisk's NovoCare Patient Assistance Program provides Tresiba at no cost to qualifying individuals below 400% of the federal poverty level ($58,320 for a single adult in 2025). Applications are submitted through novocare.com or by calling 1-800-727-6500. [14]

The ADA's 2024 Standards of Care directly address insulin access barriers: "Providers should be aware of and use available resources to help patients obtain insulin at reduced cost, including manufacturer assistance programs, discount card programs, and therapeutic substitution with biosimilar or over-the-counter insulins when clinically appropriate." [4]

South Dakota's insulin-dependent population faces a documented cost-adherence problem. A 2022 Health Affairs analysis found that 16.5% of insulin users in the United States reported cost-related underuse of insulin in the prior 12 months, with rates highest in states without state-level insulin cost-cap laws. [15] South Dakota has not enacted a state insulin cost-cap law as of 2026, meaning the $35 per month cash-pay price via discount card and the Novo Nordisk assistance programs remain the primary safety net for uninsured SD patients.

How Tresiba Compares to Other Basal Insulins Available in South Dakota

Understanding Tresiba's clinical profile matters for insurance appeal letters and shared decision-making conversations. Insulin degludec (Tresiba) differs from insulin glargine U-100 (Lantus, Basaglar), insulin glargine U-300 (Toujeo), and insulin detemir (Levemir) in three measurable ways.

First, the half-life. Tresiba's terminal half-life is approximately 25 hours, roughly twice that of glargine U-100 at 12 hours. [1] This means missed or delayed doses are less likely to produce hyperglycemia, a practical advantage for patients with irregular schedules.

Second, hypoglycemia rates. DEVOTE (N=7,637) showed a 40% lower rate of severe hypoglycemia with insulin degludec versus insulin glargine U-100 (rate ratio 0.60, P<0.001), a difference that held in the subgroup of patients with prior severe hypoglycemia (rate ratio 0.49). [2] Severe hypoglycemia carries real economic cost: a 2019 analysis in Diabetes Care estimated the average per-event medical cost of a severe hypoglycemic episode at $1,387, which contextualizes the $35 per month premium over a preferred generic basal insulin. [16]

Third, dosing flexibility. Tresiba can be administered at any time of day with a minimum of 8 hours between injections, unlike glargine U-100, which is optimally given at the same time each day. The ADA/EASD 2020 consensus report on type 2 diabetes pharmacotherapy notes this flexibility as clinically meaningful for patients with shift-work schedules or unpredictable meal timing. [4]

For South Dakota prescribers writing PA letters to SD Medicaid or commercial insurers, citing the 40% severe hypoglycemia reduction from DEVOTE and the Endocrine Society's guideline preference for insulin degludec in hypoglycemia-prone patients provides a defensible clinical rationale. [7]

Levemir (insulin detemir), which Novo Nordisk discontinued in the United States in December 2023, is no longer available as a Tresiba alternative. Patients previously stabilized on Levemir have often transitioned to Tresiba, Toujeo, or biosimilar glargine products. [17]

Titration, Monitoring, and Follow-Up for South Dakota Telehealth Patients

Starting Tresiba safely requires a clear titration protocol and a follow-up plan. For type 2 patients new to basal insulin, the ADA recommends beginning at 10 units subcutaneously once daily, measuring fasting blood glucose each morning, and increasing the dose by 2 units every 3 days until fasting glucose consistently falls between 80 and 130 mg/dL. [4]

Type 1 patients transitioning from another basal insulin to Tresiba should start at the same unit-for-unit dose of their previous basal insulin with instructions to contact their provider within 72 hours. The FDA label notes that dose adjustments may be needed due to Tresiba's longer action profile when converting from shorter-acting basal insulins. [1]

Monitoring targets per ADA 2024 standards include an HbA1c below 7.0% for most non-pregnant adults, with less stringent targets (below 8.0%) acceptable for patients with limited life expectancy, extensive comorbidities, or a history of severe hypoglycemia. [4] Renal function monitoring matters because insulin clearance changes with advancing chronic kidney disease; patients with an eGFR <30 mL/min/1.73m2 may require dose reductions. [1]

Follow-up labs at 3 months (HbA1c, basic metabolic panel) and annual comprehensive metabolic screening align with both ADA and AACE guidelines for patients on basal insulin therapy. The American Association of Clinical Endocrinology's 2022 algorithm recommends structured self-monitoring of blood glucose at least twice daily for patients on basal insulin, with continuous glucose monitor (CGM) use preferred when cost and access allow. [18]

South Dakota residents using telehealth can transmit CGM data, glucose logs, and lab results directly through secure patient portals, making remote titration feasible for the state's large rural population. A telehealth visit combined with quarterly lab orders through a local SD lab (Sanford, Avera, or Monument Health operate draw sites statewide) provides equivalent monitoring to in-person endocrinology follow-up for stable basal-only insulin regimens. [11]